Name: Deferoxamine mesylate
Brand: Selleck Chemicals
SKU: S5742
Rating: 5 (117 reviews)

바로가기

품질 관리

배치: 순도: 99.74%

99.74

함께 자주 사용되는 제품 Deferoxamine mesylate

Z-VAD-FMK

It can reverse the cell proliferative activity of granulosa cells in EMFF but not Z-VAD-FMK.

Ferrostatin-1 (Fer-1)

It and Ferrostatin-1 can reverse the cell proliferative activity of granulosa cells in EMFF.

SRS11-92

It can reverse the cell proliferative activity of granulosa cells in EMFF but not Necrostatin-1.

관련 타겟	CXCR Autophagy Nrf2 Mitophagy LRRK2 ULK FKBP Heme Oxygenase cGAS LC3
기타 Ferroptosis 억제제	Liproxstatin-1 RSL3 Erastin Imidazole Ketone Erastin (IKE) FIN56 iFSP1 UAMC-3203 SRS16-86 icFSP1 N6F11

세포 배양, 처리 및 작업 농도

세포주	분석 유형	농도	배양 시간	활성 설명	PMID
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM.	17602603
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM.	19601577
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM.	19216562
A549	Antiproliferative assay		72 hrs	Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM.	22861499
SK-N-MC	Antiproliferative assay		96 hrs	Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM.	17064069
MDCK	Toxicity assay			Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM.	20041672
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM.	20303768
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
DMS53	Antiproliferative assay		72 hrs	Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM.	22861499
SK-MN-C	Antiproliferative assay			Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM.	18159922
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM.	22858101
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM.	17963372
SK-N-MC	Toxicity assay			Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM.	20041672
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM.	28841514
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	21055950
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM.	22172311
U2OS	Function assay		30 mins	Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM.	22172704
HL60	Cytotoxicity assay			Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM.	23266185
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM.	23312948
SK-N-MC	Antiproliferative assay			Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM.	19601577
SK-N-MC	Antiproliferative assay		72 hrs	Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM.	21846118
SK-N-MC	Cytotoxicity assay		72 hrs	Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM.	23276209
K562	Cytotoxicity assay			Cytotoxicity against human K562 cells, GI50 = 33.1 μM.	23266185
HT29	Cytotoxicity assay		72 hrs	Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM.	18345610
HT-29	Cell cycle assay	10 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs	20353152
HT-29	Cell cycle assay	5 uM	24 hrs	Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs	20353152
HCT116	Function assay		24 hrs	Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3	24900837
HeLa	Bacteriostatic assay	>100 uM	1 hr	Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy	25027937
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay	28285915
SK-N-BE(2)-M17	Cytoprotection assay	1 mM	2 hrs	Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay	28285915
DAOY	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
BT-37	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
SK-N-SH	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
BT-12	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS assay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량	656.79	화학식	C₂₆H₅₂N₆O₁₁S	보관 (수령일로부터)	3 years -20°C powder
CAS 번호	138-14-7	--		원액 보관	1년-80°C용매에 보관 1개월-20°C용매에 보관

용해도

In vitro
배치:

DMSO : 100 mg/mL (152.25 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : 100 mg/mL

Ethanol : Insoluble

DMSO : 100 mg/mL (152.25 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : 100 mg/mL

Ethanol : Insoluble

DMSO : 100 mg/mL (152.25 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : 100 mg/mL

Ethanol : Insoluble

DMSO : 100 mg/mL (152.25 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : 100 mg/mL

Ethanol : Insoluble

Water : 100 mg/mL

DMSO : 50 mg/mL (76.12 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : Insoluble

몰농도 계산기

질량	농도	부피	분자량
=	×	×

희석 계산기 분자량 계산기

In vivo 배치:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Selleck 연구소에서 검증되었습니다. 이 제형에 대한 조정이 필요한 경우 맞춤 테스트를 위해 당사 영업팀에 문의하십시오.	5.000mg/ml (7.61mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

투여량: mg/kg 동물 평균 체중: g 동물당 투여량:μL 동물 수:

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH₂O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

Targets/IC₅₀/Ki	HIF-1α Beta Amyloid Ferroptosis
시험관 내(In vitro)	철 킬레이트제 및 ferroptosis 억제제인 Deferoxamine mesylate는 전신 홍반성 루푸스(SLE) 혈청에 의해 유도된 호중구 사멸을 구조하며, 이는 ferroptosis가 SLE에서 호중구 사멸의 주요 형태일 수 있음을 시사합니다.
생체 내(In vivo)	Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468)는 철 복합체를 형성하고 킬레이트제로 사용되는 Deferoxamine의 메실산염입니다.
참조	[1] https://pubmed.ncbi.nlm.nih.gov/26082716/ [2] https://pubmed.ncbi.nlm.nih.gov/30539824/ [3] https://pubmed.ncbi.nlm.nih.gov/34385713/ [4] https://pubmed.ncbi.nlm.nih.gov/2538902/

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Deferoxamine mesylate Ferroptosis 억제제

화학 구조

분자량: 656.79

품질 관리

함께 자주 사용되는 제품 Deferoxamine mesylate

세포 배양, 처리 및 작업 농도

화학 정보, 보관 및 안정성

용해도

몰농도 계산기

생체 내 제형 계산기 (투명한 용액)

작용 메커니즘

기술 지원